This article summarizes work published in the International Journal of Cancer and discusses how researchers evaluated antitumor activity in three patient-derived xenograft models.
They used Inotiv’s athymic nude mice to study the effectiveness of an oral bioavailable small molecule as a potential treatment option.
Along with the preliminary results, this case study also discusses the advantages of the Athymic Nude Mouse to support patient-derived xenografts (PDX).
Download this case study and explore:
-
Reproducing the biological and pharmacological features of a human tumor in the Athymic Nude Mouse
-
The benefits of creating a patient-derived xenograft with the Athymic Nude Mouse
-
How Inotiv can enable innovative research for rare disease studies
Complete the form to the right to request a copy of the case study.
